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Abstract 
Dry coating techniques enable manufacturing of coated solid dosage forms with no, or very limited, 
use of solvents. As a result, major drawbacks associated with both organic solvents and aqueous 
coating systems can be overcome, such as toxicological, environmental and safety-related issues on 
one hand as well as costly drying phases and impaired product stability on the other. The 
considerable advantages related to solventless coating has been prompting a strong research interest 
in this field of pharmaceutics. In the present article, processes and applications relevant to 
techniques intended for dry coating are analyzed and reviewed. Based on the physical state of the 
coat-forming agents, liquid- and solid-based techniques are distinguished. The former include hot-
melt coating and coating by photocuring, while the latter encompass press coating and powder 
coating. Moreover, solventless techniques, such as injection molding and 3D printing by fused 
deposition modeling, which are not purposely conceived for coating, are also discussed in that they 
would open new perspectives in the manufacturing of coated-like dosage forms. 
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List of substance acronyms 
 
AMG  acetylated monoglyceride 
EC  ethyl cellulose  
GMS  glyceryl monostearate 
HEC  hydroxyethyl cellulose  
HPC  hydroxypropyl cellulose 
HPMC  hydroxypropyl methylcellulose 
HPMCAS hydroxypropyl methylcellulose acetate succinate 
PEG  polyethylene glycol 
PEO  polyethylene oxide 
PVP  polyvinylpyrrolidone 
TEC  triethyl citrate 
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1.  Introduction 
Manufacturing of coated solid dosage forms entails the deposition of different materials onto 
substrate cores, such as powder, granules, pellets, tablets and capsules, with the aim of achieving 
superior organoleptic and aesthetic characteristics, providing physical and chemical protection or 
modifying the drug release profile.  
Conventional coating techniques, carried out by fluid bed or rotating pan equipment, involve 
spraying of a solution or suspension of the coating material(s) in an organic and/or aqueous vehicle, 
which generally represents not less than 70% w/w of the composition [1]. 
The use of organic solvents was preferred in the past as it enables shorter processing times and 
straightforward film formation. In more recent times, increasingly strict toxicological, 
environmental and safety-related requirements have led to progressive replacement of organic 
solvent- with aqueous-based coating, which may lower the overall manufacturing costs. 
Nevertheless, aqueous systems involve long and expensive drying phases, to remove the large 
amounts of water used, and frequently bring about stability issues. Indeed, because water migration 
may occur during the coating process or within storage, aqueous systems turn out unsuitable not 
only when moisture-sensitive bioactive compounds are dealt with, but also when the overall quality 
of the final product may be affected by humidity. 
Hence, in view of the many issues associated with the use of solvents of whatever nature, 
alternative procedures or novel applications of well-established ones have been proposed over the 
years to improve pharmaceutical coating. Techniques that are generally referred to as “solventless” 
or “dry coating” include manufacturing methods that completely avoid solvents or at least markedly 
reduce the solvent to coating material ratio [2–4].  
Notably, amounts of liquid <50% w/w on the solid material have long been employed in powder 
deposition processes, such as sugar coating derived from confectionary industry. This also applies 
to the layering of solid drugs onto inert seeds, wherein aqueous binding formulations are added to 
promote particle adhesion and cohesion. An attempt to exploit the powder layering technique for 
coating has recently been described. In this case, a swellable/erodible polymer (HPMC) powder was 
applied to drug-containing tablets for the manufacturing of a coated oral delivery system for time-
controlled release [5]. 
Techniques that would properly be identified as dry coating processes may be classified relying on 
the physical state of the coat-forming agents when applied onto the substrate (Figure 1) [6]. 
Accordingly, liquid- or solid-based techniques are distinguished in this review article. In the first 
ones, melts or liquid precursors applied to the core surface are consolidated by cooling (hot-melt 
coating) or polymerization (coating by photocuring), respectively, to give a continuous layer. In 
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solid-based techniques, the coating material is directly applied to the substrate by compression 
(press coating), or else it can be layered and simultaneously consolidated by heating (powder 
coating). When layering is performed, the process can be improved, especially as regards the initial 
deposition phases, by spraying liquid aids and/or through the use of electrically charged powder 
particles.  
In addition, innovative solventless techniques based on hot processing of thermoplastic materials 
allow the manufacturing of core+shell systems or of capsular devices comprising a functional shell 
and an inner drug formulation. Although not attained through any standard coating procedures, both 
such dosage forms may be regarded as “coated-like”, and specific examples are reviewed in this 
article. 
 
2. Liquid-based techniques  
2.1.  Hot-melt coating  
In hot-melt coating processes, low-melting materials are deposited in the liquid state onto the 
surface of the cores, generally by spraying, and subsequently congealed in a controlled manner [7]. 
Such operations are commonly carried out by rotating pan or fluid bed for the manufacturing of 
coated pellets and granules. When the coating material is sprayed, it needs to be maintained at 40–
60°C above its melting point [2,7,8]. The temperature represents the most critical process parameter 
and has to strictly be controlled in any part of the equipment. For this reason, the tubes through 
which the molten materials are conveyed from the reservoir to the spray nozzle have to be heated 
and/or properly insulated to prevent undesired cooling and consequent plugging. Moreover, nozzles 
purposely devised for spraying of melts may be needed. In particular, a triaxial nozzle structure 
comprising a central tube for supply of the coating agent, surrounded by a cavity for nebulizing air 
flow, enclosed within a further cavity for heated compressed air has been described (Figure 2) [9]. 
The nozzle should also be insulated to prevent re-melting of the applied coating upon contact of the 
units with its hot surface. Besides, it should correctly be located in the processing chamber thus 
enabling efficient deposition of droplets.  
As a general rule, the spray rate has to be remarkably lower and more strictly controlled in hot-melt 
as compared with solvent-based coating, in order to achieve homogeneous distribution of the 
coating material and avoid agglomeration of the units. On the other hand, the overall processing 
time can be much shorter because no solvent removal is required. Indeed, the formula of the 
sprayed material corresponds to that of the final coating. 
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Easy flowing and sprayability of the melt are fundamental requisites for an excipient to be selected 
as a coating agent. These characteristics are generally satisfied by materials having <80°C melting 
point and <300 cps melt viscosity [2].  
An alternative to spraying of the coating agent is represented by its direct addition to the core bed in 
the form of solid particles, thus having it melted in situ [10–13]. Subsequent cooling allows the melt 
deposited to solidify. In this case, reduction of equipment costs and simplified setup as well as 
cleaning operations are in principle possible, because spraying devices, thermostatic jackets and 
other related appliances are not required. The use of a hot air operated venturimeter has also been 
proposed to simultaneously fluidize core granules and a low-melting coating agent [14–16]. In this 
equipment, hot air is injected into a pipe, which aspires, by Venturi effect, the blend of solid 
materials introduced by a vibrating funnel, thus providing automatic feeding of the device. The 
blend, driven by a non-turbulent flux of air, moves forward within a thermostated path, along which 
melting of the coating material occurs, mainly at the particle surface. Subsequent falling of the 
cores at room temperature enables formation of a continuous coating by re-solidification. 
In hot-melt coating, fatty acids, partially hydrogenated vegetable oils, glycerol esters, waxes and 
PEGs have broadly been employed [9,17]. A critical issue in the use of lipid coating agents of plant 
or animal origin is batch-to-batch reproducibility of their physico-chemical characteristics, which 
may affect consistency of processing and product performance. 
Hot-melt coating has mainly been used for the production of prolonged-release formulations 
[11,12,18–22]. Nonetheless, taste-masked or moisture-protected dosage forms for immediate 
release have also been obtained [10,13,23,24]. 
In Table I, the main pharmaceutical applications of hot-melt coating and relevant process details are 
summarized.  
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2.2. Coating by photocuring 
Photocuring, also known as light-curing or polymerization coating, provides a chemical approach to 
the attainment of coating layers exploited in many industrial fields and for medical applications [2]. 
It involves polymerization of functionalized liquid precursors (pre-polymers or monomers) in the 
presence of an initiator or a photosensitizer, and takes place at room temperature or below, resulting 
in rapid formation of a cross-linked network. This reaction is triggered by UV or visible light and 
may be based on free radical, cationic or anionic mechanisms depending on the nature of the 
precursors and initiators used. Equipment for photocuring needs to be provided with a light source, 
and a nitrogen purging system may also be necessary when the outcome of coating would be 
impaired by the presence of oxygen in the reaction environment. 
A major advantage of photocuring over other solventless techniques is the possibility of operating at 
relatively low temperatures within short processing times, making this coating method appropriate 
for heat-sensitive compounds. However, photocuring appears to have a narrow potential for 
application in the pharmaceutical field on account of toxicological constraints, poor availability of 
proper starting materials and unsuitability for use in the case of photosensitive drug molecules. 
Indeed, only few examples of coating by photocuring are described in the literature. A number of 
these concerns UV light-induced coating of pellets with siloxane materials, which required the 
incorporation of various solid pore forming agents for drug release modulation [25–27]. More 
recently, two methacrylate monomers, extensively utilized in dental composites, were polymerized 
on the surface of pellet cores by means of visible light [28,29]. Photostable functional coatings able 
to withstand handling stresses were successfully achieved, and an impact on the final release profile 
was observed as a function of their composition and thickness. 
An analogous coating technique, initially exploited in the pharmaceutical field for encapsulation of 
particles, is the initiated chemical vapor deposition [30]. As the name suggests, gaseous 
formulations, consisting of vaporized monomers and initiators, are involved. In this case, a thin 
coating layer is formed when the monomers, along with primary radicals generated by heat 
activation of the initiator, are adsorbed onto the surface of cooled particles, where polymerization 
occurs. Depending on the monomers used, differing functional coatings were obtained, including 
gastroresistant, temperature-responsive and prolonged-release ones [31–35]. Furthermore, the 
application of a polymeric coating by initiated chemical vapor deposition, synthesized from acrylic 
precursors directly upon clotrimazole-containing cast films, was recently demonstrated to be a 
viable approach to prevent crystalline transitions of amorphous compounds [36]. 
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3. Solid-based techniques 
3.1 Press coating 
Press coating, also referred to as double compression or compression coating, has largely been 
employed since the first pharmaceutical application was described in the late 50s [37]. 
This technique entails (i) filling of the die of a tableting machine with one half of the overall 
amount of coating powder formulation, (ii) positioning of the tablet core onto the powder bed, (iii) 
filling of the die with the remainder of the powder and (iv) final compression to consolidate the 
applied material into an outer layer of defined thickness.  
In order to avoid multi-step processes and circumvent the critical operation of positioning the core 
inside the die, which may impair the coat thickness homogeneity, a one-step manufacturing method 
was proposed based on the use of special tableting equipment [38]. 
The use of double compression necessarily leads to coatings having relatively high thickness, with 
possible undesired repercussions on the dissolution/release performance, and is limited to cores 
with appropriate physico-technological characteristics in terms of size, shape and mechanical 
resistance. Moreover, coating materials with adequate compaction properties can only be applied, 
and the addition of excipients may be required to improve the outcome of compression. 
Although more advantageous techniques, such as spray coating, have been introduced so far, the 
use of compression coating is still described chiefly for the application of functional polymer 
coatings intended for modified release [39–42]. In this respect, swellable hydrophilic and 
microbially degradable polymers have mostly been employed for the purpose of attaining 
prolonged, pulsatile or colonic oral drug delivery systems. Among swellable hydrophilic polymers, 
cellulose derivatives, namely HPMC [43–49], HPC [50] and HEC [51], have especially been 
utilized because of their broad availability at affordable costs and acceptable compaction properties. 
Although less frequently, the use of PEO has also been reported [52–54]. Coating formulations 
based on polysaccharides of natural origin, mainly pectin [55–57], guar gum [58,59], xanthan gum 
[59] and locust bean gum [60] have extensively been employed especially due to their 
biodegradability by colonic bacteria. The latter two materials were employed in admixture as 
compression coating agents for the SyncroDose™ chronotherapeutic delivery platform based on the 
TIMERx
®
 proprietary technology (Penwest Pharmaceuticals Co.) [61,62]. 
Enteric polymers (Eudragit
®
S, Eudragit
®
L and HPMCAS) were also applied by press coating with 
the aim of attaining pH-dependent systems for colonic release [63–65]. 
Finally, based on mixed wax and brittle materials as the coating agents, a press-coated delivery 
platform (Geoclock™) was developed, and a related prednisone-containing product (Lodotra™, 
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Mundipharma Pharmaceuticals Srl) is commercially available for chronopharmaceutical treatment 
of early-morning stiffness associated with rheumatoid arthritis [66]. 
In Table II, the main pharmaceutical applications of press coating and relevant process details are 
summarized. 
 
3.2 Powder coating 
Powder coating techniques involve the deposition of multiple layers of powder, the consolidation of 
which occurs through particle modifications prompted by heat. Indeed, after initial spreading and 
adhesion of particles to the substrate, possibly favored by the application of a priming sub-coating 
of a different material, their heat-induced softening, deformation and coalescence are necessary for 
a smooth and continuous layer to be formed. Levelling and sintering of the powder layers applied is 
strictly dependent on the thermo-mechanical behavior of the material at the operating temperature 
and is aided by the mechanical forces involved. The process has to be carried out above the glassy-
rubbery transition temperature (Tg) of the coating formulation so that the particles may undergo 
plastic deformation. For this reason, plasticizers are often added to lower the Tg of the coating 
agent, also allowing milder processing conditions to be adopted. 
Such techniques generally make use of conventional coating equipment (e.g. fluid bed and rotating 
pan) provided with devices for the in-line addition of the powder into the processing chamber. The 
rate of powder feeding can be controlled by single-screw, loss-in-weight or Venturi feeder devices 
(Figure 3). In all cases, attentive selection of particle size ranges and appropriate flow properties of 
powder formulations are necessary to ensure reproducibility of the coating thickness.  
Powder coating techniques can be classified into thermal adhesion, liquid-assisted and electrostatic 
processes depending on whether aiding factors are used to promote particle adhesion and, if so, on 
what factor is concerned (Figure 4).   
 
3.2.1 Thermal adhesion coating  
In thermal adhesion coating, elsewhere referred to as heat dry coating, the formation of a coating 
from layered powders is enabled by heat only [3]. The thermal properties of the coating powder are 
therefore critical to the outcome of the process.  
Plasticizer concentrations up to 40% and thermal post-processing treatments (curing) are generally 
necessary to enhance the coalescence of particles and allow films of good quality to be formed. Pre-
plasticized polymers, obtained by hot-melt extrusion (HME) followed by cryogenic grinding, are 
generally employed. Talc is normally present in the powder formula to prevent sticking of the units. 
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The few applications of thermal adhesion described in the literature all rely on the use of acrylic 
polymers. An existing manufacturing equipment, namely a spheronizer provided with a smooth 
stainless steel disk, was adapted through the addition of a powder feeding device and an IR lamp 
positioned on top as a heating source to maintain constant processing temperatures. 
In one case, effectively taste-masked and moisture-protected tablets were achieved without 
plasticizers, thanks to the relatively low Tg of the polymer employed (Eudragit
®
E PO) [67]. 
However, an extensive curing phase was required for a continuous and compact film to be obtained, 
and the inclusion of low-melting excipients in the coating formulation was found to improve 
powder adhesion.  
In another instance, pre-plasticized mixtures of Eudragit
®
RS and Eudragit
®
RL, prepared by HME, 
were applied onto theophylline-containing tablets having a sub-coating of a low melting material 
[68]. The rate of drug release from the final powder-coated tablets was influenced by the coating 
level, the plasticizer concentration and the temperature selected for the curing phase. 
Finally, Eudragit
®
L 100-coated tablets containing two different water soluble drugs were also 
manufactured [69–71]. Formulation variables, such as the nature sub-coating material, the level of 
plasticizer and the type as well as amount of pore-forming agents, were demonstrated to impact on 
the mechanical and drug release properties of the coated units. 
 
3.2.2 Liquid-assisted coating  
In liquid-assisted dry coating, small amounts of water or aqueous binding solutions are sprayed to 
help, by interfacial capillary action, adhesion of coating particles to the core surface. In order to 
completely replace the use of solvents, liquid excipients that are intended to be included in the 
coating, such as plasticizers, can be employed, which also results in improved particle coalescence. 
In this respect, a larger amount of plasticizers is generally necessary for film formation in dry- as 
compared with spray coating techniques.  
The adjuvants in  the liquid state are added separately from the powder, in a concurrent or alternate 
mode. Therefore, rotating pans or fluid beds may be provided with a conventional nozzle for 
spraying of liquids, whereas the coating powder is introduced in admixture with the cores, or by 
means of powder feeding devices. Otherwise, a three-way nozzle, generally inserted within the core 
bed, can be adopted to have liquid and powder delivered in close proximity to each other (Figure 5).  
A recently proposed alternative to the spraying of plasticizers in the liquid state is represented by 
their use as powders. These would be spread onto pre-heated core/polymer mixtures inside the 
coating chamber through two-fluid nozzles based on Venturi effect [72].  
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In the earliest application of liquid-assisted dry coating, HPMCAS was layered onto pellets and 
tablets with the aid of a plasticizing mixture consisting of TEC and AMG [73]. The process was 
performed by different apparatuses, such as a centrifugal granulator, a fluid bed and a ventilated pan 
coater. After completion of powder feeding, small volumes of water or of an aqueous HPMC 
solution were sprayed to improve film formation during the curing phase. Although the use of water 
was not fully avoided, it was possible to reduce the process time to one third as compared with that 
required by conventional spray coating. By adapting the above-described coating procedure, 
HPMCAS was also applied to soft gelatin capsules by rotary fluid bed [74]. At first, plasticizers 
alone were sprayed to prime the capsule surface thus limiting the loss of powder in the early stages 
of coating. However, due to the adhesive properties of the substrate, HPMCAS needed to be pre-
mixed with relatively large amounts of talc in order to overcome sticking of the units.  
Silicon dioxide in very limited amounts was investigated as an alternative anti-sticking agent for 
the coating of pellets with HPMCAS by rotary fluid bed apparatus [75]. Again, TEC and/or AMG 
were used as plasticizers in the liquid state, and a curing phase was performed [76–79]. An in-
depth understanding of the formulation and processing parameters that affect film formation, 
coating efficiency and storage stability was gained, also by making use of a factorial design of 
experiments. In other studies, carried out under the same experimental settings, the role of AMG, 
isopropyl myristate and isopropyl palmitate as capillary force promoters was highlighted. Such 
compounds proved effective in improving the adhesion of the polymer onto the cores and 
enhancing the coating efficiency [80,81]. Moreover, liquid adjuvants having good spreading 
ability, as assessed through contact angle measurements with respect to the coating polymer, were 
found advantageous for the development of efficient dry coating processes [82]. 
Recently, liquid-assisted dry coating was exploited to apply HPMCAS onto pellets containing 
probiotics [83]. Notably, this process allowed higher bacterial survival rates to be attained as 
compared with conventional coating techniques. 
Polymeric materials other than HPMCAS, such as shellac, Eudragit
®
 RS and EC, were also used in 
dry coating. The latter two materials were employed as coating agents for prolonged-release dosage 
forms [84–86]. In all cases, emulsions of plasticizers with an aqueous solution of HPMC were 
sprayed. The release rate from the coated units turned out to be affected by the type and level of 
plasticizer as well as by the curing conditions, whereas the physical stability of the product was 
improved by the use of micronized coating powders. 
In another instance, pre-plasticized EC was used as the coating polymer. Pre-plasticization was 
obtained by HME co-processing or adding the plasticizer(s) to commercially available aqueous 
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polymer dispersions (Aquacoat
®
, Surelease
®
), which were then spray-dried to yield powders 
suitable for dry coating [87]. 
 
3.2.3 Electrostatic coating 
Coating procedures based on electrostatic charging of powders are well-established in the metal-
finishing industry and are now of interest also for the development of drug dosage forms and 
medical devices [3].  
In pharmaceutical coating, electrostatic forces are exploited to promote the adhesion of powder 
particles to the substrates, mainly tablets or pellets. The process is generally carried out by 
grounded rotating pans provided with an electrostatic gun, through which the coating particles are 
charged via differing mechanisms and sprayed onto the cores [88]. After deposition, the powder has 
to remain in place long enough to enable film formation by heat-induced coalescence of the 
individual particles. A smooth and homogeneously thick coating is achieved by reduction of the 
free volume, while its hardening takes place on cooling [89]. Any powder able to accumulate 
charge with a low decay rate is potentially suitable for being employed as an electrostatic dry 
coating agent [90].  
Because many materials of pharmaceutical interest can retain electric charges, powder charging has 
been used not only for coating but also in other manufacturing operations. For example, it was 
exploited to improve the active pharmaceutical ingredient (API) content uniformity in mixing, and 
to obtain thin films by solvent-free deposition of API/polymer blends [91–93].  
Electrostatic charging of particles may be obtained via a triboelectric or corona mechanism. In 
tribocharging, charge accumulation results from friction between the fluidized coating particles and 
the wall of a triboelectric gun, according to the well-known phenomenon of electron transfer that 
occurs when different materials are rubbed with each other and then separated. The same 
mechanism is operating when charges are generated during powder handling in several 
pharmaceutical processes. The gun wall is generally made of polytetrafluoroethylene that tends to 
assume negative charges, thereby leading to positively charged particles. Tribocharging is rather a 
complex and poorly predictable operation because it is markedly influenced by many factors, such 
as particle properties (electrical resistivity and surface roughness) and environmental conditions 
(temperature, relative humidity) [90,94,95]. For this reason, triboelectric charging is less commonly 
effected than corona charging. 
Corona charging, also referred to as corona discharge, entails that particles accumulate charges onto 
their surface by crossing an electric field in the presence of free ions. Corona gun devices include an 
electrode able to generate a potential gradient with a neutral or grounded substrate when a high 
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voltage is applied. This allows free ions to be obtained by stripping electrons from gas molecules 
surrounding the electrode. Therefore, the coating particles, sprayed by the gun in the direction of the 
substrates to be coated, are introduced into the electric field that has established in the area between 
the emitting electrode and the grounded surface. According to the field charging mechanism, the 
perturbation of the field provoked by the particles results in free ion deviation and adsorption.  
A major drawback of corona charging is the possible accumulation of charges on the surface of the 
substrate, which would prevent adhesion of further coating particles. Moreover, the oppositely 
charged ions that are formed may neutralize the incoming charged particles and, also, those already 
deposited, possibly causing their ejection from the coating layer and consequent defects in its 
surface. 
In electrostatic coating, it is often necessary to enhance the conductivity of the core dosage forms. 
In this respect, a short-lasting exposure of the substrate to high humidity conditions was proposed 
with the aim of having water molecules adsorbed prior to powder deposition [96]. More recently, 
the spraying of small amounts of plasticizers in the liquid state was alternatively undertaken. Thus, 
not only the electrostatic deposition of particles was enhanced, but also their adhesion and 
coalescence could be improved, by capillary action and Tg reduction, respectively. The combined 
use of liquids and electrostatic charging was successfully applied to the coating of tablets and 
pellets with different polymers, intended for immediate, prolonged or enteric release [97–101]. 
In particular, the coating efficiency was found higher when employing both electrostatic charging 
and plasticizers in the liquid state as compared with the sole plasticizers. Moreover, it turned out to 
be influenced  by the charging voltage of the electrostatic gun [99,100]. 
An example of industrial application of electrostatic dry powder coating is represented by 
LeQtracoat
®
 technology (Diurnal Group PLC), developed by Phoqus Pharmaceuticals [102]. In a 
custom-designed equipment, the coating of tablets takes place according to the same principle used 
in photocopying for the deposition of ink toner. The coating material is applied to one side first and 
then to the other. The extent of precision allowed is such that images (brands, signs) can be 
imprinted on the tablet surface. By LeQtracoat
®
 technology, clinical batches of Chronocort
®
, a 
modified-release formulation of hydrocortisone for the treatment of adrenal hyperplasia, were 
manufactured [103,104].  
In Tables III-V, the main pharmaceutical applications of powder coating techniques, namely 
thermal adhesion, liquid-assisted and electrostatic coating, respectively, are summarized along with 
the relevant process details. 
 
 
13 
 
 
4. Other techniques  
Different techniques based on hot processing of thermoplastic polymers, widely exploited in many 
industrial areas albeit only marginally in the pharmaceutical field, are deemed to fall within the 
scope of this review article in that they allow coated-like dosage forms to be manufactured without 
the use of solvents. Such dosage forms may be presented in the form of core+shell systems or of 
capsular devices consisting in functional shells filled with drug formulations.  
Injection molding (IM) and three-dimensional (3D) printing by fused deposition modeling (FDM) 
are the main solventless techniques employed for fabrication of coated-like dosage forms. While IM 
holds great potential with respect to its possible suitability for continuous manufacturing, FDM 3D 
printing is especially attractive as a real-time prototyping technique and as a tool for medicine 
personalization. 
In IM, a properly softened or melted material is injected, under high pressure conditions, into a 3D 
mold, by which it is shaped into the finished item on cooling [105]. IM represents a versatile 
manufacturing technique in that it enables the production of objects with different size and shape as 
well as detailed geometries. Over the last years, it has drawn much attention due to its viable 
exploitation in either the manufacturing of consolidated dosage forms or the development of 
original delivery systems with peculiar design and enhanced therapeutic performance.  
A capsular device obtained by IM was proposed for extended residence within specific regions of 
the gastrointestinal tract [106]. For this purpose, a small magnet was inserted into the capsule, 
which could be kept at the target site by positioning an external control magnet in the corresponding 
area of the body surface. Such a device was manufactured starting from polymers that were 
demonstrated to be biodegradable to a different extent.  
Egalet
®
 is a delivery platform produced by IM and developed for either prolonged or pulsatile 
release [107]. In the prolonged-release configuration, it consists in a drug-containing hydrophilic 
erodible matrix enclosed within a shell provided with two openings at each end, composed of an 
insoluble and impermeable polymer. The rate of drug release from the inner matrix is controlled 
through a diffusion/erosion-based mechanism. Because only the two bases of the matrix come into 
contact with the gastrointestinal fluids, zero-order kinetics can be achieved, which is exploited for 
reducing the daily frequency of drug dosing, particularly with opioids in pain management. In this 
instance, the formulation is specifically conceived to resist physical and chemical manipulation 
methods, thus lowering the risk of misuse and addiction (Egalet Guardian
TM
 Technology) [108]. 
The Egalet
®
 system in its pulsatile-release configuration was attained by positioning, at the open 
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ends of the shell, two erodible polymer plugs able to impart a delay phase through their surface 
erosion. The core and shell components of these devices were basically fabricated by one-step IM 
processes involving two successive injections from distinct nozzles into a single mold, wherein 
cavities to be filled with the concerned materials were timely created by the alternate movement of 
a plunger. 
The Chronocap
®
 delivery platform consists in a functional capsular container formed from a cap 
and a body, able to convey differing drug formulations [109]. The release of the active molecule can 
be modulated by selecting the appropriate composition (type of polymer, presence of other 
excipients) and design characteristics (geometry, wall thickness) for the shell. Capsular devices 
based on swellable/erodible (HPC) or enteric-soluble (HPMCAS) polymers were obtained by IM 
after design of special molds [110,111]. The HPC shells, filled with a model drug, were shown to 
give rise to pulsatile release, lag time being related to their thickness. Such a system was proposed 
for time-dependent colon delivery following application of a gastroresistant outer film by spray 
coating [112]. 
As any 3D printing process, FDM is an additive manufacturing approach that involves the 
deposition of successive layers of material to construct objects from their digital models. In this 
technique, the printer is fed with filaments produced by HME, and the thermoplastic material, 
properly melted/softened, is applied by a heated extrusion head moving along the x and y axes 
above a build plate that moves along the z axis. The item under construction thus grows in the 
bottom-up direction [113].  
The Chronocap
®
 system for pulsatile release was also fabricated by FDM, showing comparable 
performance versus a reference formulation produced by IM [114]. This finding pointed out the 
potential advantages such a technique may offer not only as a manufacturing strategy for 
personalized drug delivery but also as a rapid prototyping tool for the molded capsular device. 
Finally, by means of a dual 3D printer, suitable for concurrent deposition of different materials, a 
gastroresistant tablet was recently produced [115]. The enteric-soluble shell and the drug-containing 
core, made of Eudragit
®
L 100 and PVP, respectively, were shaped within a single-step process.  
 
 
5. Conclusions  
In the pharmaceutical field, dry coating techniques are proposed with the aim of avoiding or 
limiting the drawbacks associated with the use of solvents. Although spray coating definitely 
remains the most popular approach to attaining coated dosage forms, the need for processes suitable 
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for water-sensitive drugs or formulations, together with an increasing demand for less costly 
production, has been prompting the research in this area of pharmaceutical technology.  
Among the diverse processes discussed in this overview, traditional and well-established press 
coating, exploited for the manufacturing of a number of commercially available products developed 
in the past, is currently proposed for fabrication of oral delivery systems mainly intended for 
pulsatile, colonic or prolonged release when other techniques are not viable.  
Besides press coating, which involves utilization of conventional or customized tableting machines, 
other techniques, particularly melt coating and powder coating, rely on already available equipment 
following proper adaptation to the specific operating modes and conditions. Such techniques may 
thus have concrete chances of industrial application, provided that appropriate large-scale facilities 
can be developed. On the other hand, in the case of less consolidated processes, such as photocuring 
and initiated chemical vapor deposition, more difficulties are likely to be encountered not only 
because of the technical issues related to the construction of purposely devised apparatuses, but also 
due to the safety constraints and consequent regulatory burden to be faced. 
More recently, on account of the growing popularity of hot-processing techniques, innovative 
approaches intended for attainment of coated-like dosage forms, based on IM or FDM 3D printing, 
have increasingly been investigated as an alternative to standard coating procedures and are being 
looked at as a topic of great interest for the future of pharmaceutical manufacturing.  
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FIGURE CAPTIONS 
 
Figure 1: classification of solventless techniques used to obtain coated or coated-like dosage 
forms.  
 
Figure 2: nozzle for hot-melt coating having triaxial structure without (left) and with (right) 
Teflon insulation: entries for a) melted coating material, b) nebulizing air flow, c) heated 
compressed air (Adapted from [9]). 
 
Figure 3: rotating pan equipped with a powder-feeding device (Courtesy of IMA S.p.A., 
Italy). 
 
Figure 4: outline of dry powder coating techniques. 
 
Figure 5: three-way nozzle (left) and rotor insert of a fluid bed (GPCG 1.1, Glatt
®
, 
Germany) with the nozzle in place (right). 
 
Figure 6: cross section of a press-coated tablet. 
 
